Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
about
Implications of glial nitric oxide in neurodegenerative diseasesAntidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradationSelf-Organizing Feature Maps Identify Proteins Critical to Learning in a Mouse Model of Down SyndromePharmacological approaches to improving cognitive function in Down syndrome: current status and considerations.Pathophysiology of sleep apneaIn vivo therapeutic gas delivery for neuroprotection with echogenic liposomes.The KATP channel activator diazoxide ameliorates amyloid-β and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease.The Antinociceptive Effect of Sigma-1 Receptor Antagonist, BD1047, in a Capsaicin Induced Headache Model in RatsMicroarray analysis on human neuroblastoma cells exposed to aluminum, β(1-42)-amyloid or the β(1-42)-amyloid aluminum complex.Activity-dependent augmentation of spontaneous neurotransmission during endoplasmic reticulum stressImplications of gliotransmission for the pharmacotherapy of CNS disorders.Highly sensitive detection of S-nitrosylated proteins by capillary gel electrophoresis with laser induced fluorescence.Memantine prevents memory consolidation failure induced by soluble beta amyloid in rats.The science of stroke: mechanisms in search of treatments.Age-dependent therapeutic effect of memantine in a mouse model of juvenile Batten diseaseNeuroprotection by acetoacetate and β-hydroxybutyrate against NMDA-induced RGC damage in rat--possible involvement of kynurenic acidCalcium-sensing receptor (CaSR) as a novel target for ischemic neuroprotection.Moving towards a cure: blocking pathogenic antibodies in systemic lupus erythematosus.Amyloid-β as a modulator of synaptic plasticityHippocampal glutamate NMDA receptor loss tracks progression in Alzheimer's disease: quantitative autoradiography in postmortem human brain.Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia.Mutation of a putative S-nitrosylation site of TRPV4 protein facilitates the channel activatesProtein dynamics associated with failed and rescued learning in the Ts65Dn mouse model of Down syndrome.Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression.Neuroglobin is an endogenous neuroprotectant for retinal ganglion cells against glaucomatous damage.Treatment of post-traumatic cognitive impairments.Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation.Inhibition of a SNARE-sensitive pathway in astrocytes attenuates damage following stroke.The pharmacological challenge to tame the transient receptor potential vanilloid-1 (TRPV1) nocisensorSafety of intravitreally administered recombinant erythropoietin (an AOS thesis)Effects of memantine on neuronal structure and conditioned fear in the Tg2576 mouse model of Alzheimer's diseaseXenon-mediated neuroprotection in response to sustained, low-level excitotoxic stressLatrepirdine is a potent activator of AMP-activated protein kinase and reduces neuronal excitability.Memantine (Namenda) for neuropathic pain.Novel treatment with neuroprotective and antiviral properties against a neuroinvasive human respiratory virus.Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease.Diabetic painful and insensate neuropathy: pathogenesis and potential treatments.Protein profiles associated with context fear conditioning and their modulation by memantine.Drug therapy of post-stroke aphasia: a review of current evidence.Targeting synaptic dysfunction in Alzheimer's disease therapy.
P2860
Q26782894-E67A5FE5-A587-46DD-9B48-3FB2D8281FA2Q27319514-0ECC25D5-7499-4F0C-B64B-671B3C368C6DQ28545764-7A049871-BCE0-41FE-B03B-A49199354309Q30422188-04F6E0A5-9977-413C-8B1D-8BF2B3CCBC6EQ30440658-D730BAE1-3722-4AC0-937A-931D42729D8EQ30473667-04B7D6A4-EBCC-4873-B4D2-4C6EB3732957Q30497430-B226A045-80CB-4434-8775-734E68169416Q33574129-7356FAA8-256E-4B2B-B69D-ED7FA4A71213Q33813237-78BC847F-4B34-44BE-9908-886AD0046F39Q33942946-545B0B7B-0E54-4A34-BE89-E881A990B05EQ33971765-06B2F317-9F2E-4513-8FF3-8D5657AD52D4Q33984214-E7FC214A-41F2-4E91-8C8D-E707311599FBQ34211231-10367F3B-A7C7-4971-8334-E86B2130A7C2Q34212337-A69A2D23-E513-4914-B9C2-4444B168E8B0Q34280201-527D21EB-1CD1-46B5-B175-D6569EB6C4D6Q34280603-7CF471F7-92F4-451F-A37A-1AD574C5643DQ34455700-5F284A24-B8D7-4303-A8C5-FB3DD168D4ABQ34753885-F2D3F6CD-C13A-418B-97D8-B5E55A0805DAQ34814145-6D8A0A3C-D8D9-4D35-A316-E4F1AFB3E78AQ35060487-03D1E0E1-632F-4F4F-BC48-FC5845A913CBQ35117821-75D2E13D-BD77-45A9-BE76-232862602D7FQ35149107-12FB61BD-D89B-4385-9A8E-3675434D6F71Q35202586-095BAF8E-26D6-492B-98F6-4E7BA9E771B6Q35237104-FA670BDB-AD22-41D3-B1F2-77FBF5C4140FQ35679417-A151A9C6-87A8-45F1-B178-2D7F7D011145Q36220948-1CCE72F9-A13F-4318-BC6A-90904E96B936Q36848206-0B0A8D2A-6C36-486B-A2BD-E889415CDE24Q36975934-23250AC1-7C09-4E11-B140-8C22C56A988CQ37023861-0316D310-2777-4E89-9A20-EE4919A4FD32Q37106306-DC813406-A118-4F5B-8401-FE525376535DQ37148525-ECB37641-3DC1-40DD-B839-6F96E090DAF8Q37164290-8FC4953C-4638-4556-A41D-DFDF5B8FA719Q37281161-36E1FBEF-5FAE-4BBD-9767-BD81547287FEQ37386521-33AA1B62-5367-4959-A07F-06CFEE6C7477Q37547376-BFA8516C-D2AC-4B4F-8E2E-586A24765927Q37559812-D352A904-9516-4231-A051-96AAA11EF1B1Q37605348-86D55A5B-8657-4400-BF3F-E00A2429CE4BQ37687443-31603DF6-40D5-43DB-87AE-E84C83A4D52AQ37918433-5D3AB6D4-6BAE-4D17-B17B-6A17DBE431D1Q38036916-C245AF87-4392-4421-AEDF-FFB53835A5C1
P2860
Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Pathologically-activated thera ...... memantine and S-nitrosylation.
@ast
Pathologically-activated thera ...... memantine and S-nitrosylation.
@en
Pathologically-activated thera ...... memantine and S-nitrosylation.
@nl
type
label
Pathologically-activated thera ...... memantine and S-nitrosylation.
@ast
Pathologically-activated thera ...... memantine and S-nitrosylation.
@en
Pathologically-activated thera ...... memantine and S-nitrosylation.
@nl
prefLabel
Pathologically-activated thera ...... memantine and S-nitrosylation.
@ast
Pathologically-activated thera ...... memantine and S-nitrosylation.
@en
Pathologically-activated thera ...... memantine and S-nitrosylation.
@nl
P1433
P1476
Pathologically-activated thera ...... memantine and S-nitrosylation.
@en
P2093
Stuart A Lipton
P304
P356
10.2174/138945007780618472
P577
2007-05-01T00:00:00Z